Optic disc microvascularity in patients with intravitreal dexamethasone implantation for branch retinal vein occlusion

2021 ◽  
Author(s):  
S.T. Kaderli ◽  
A. Kaderli ◽  
S. Sül ◽  
A. Karalezli
Keyword(s):  
Retinal Vein Occlusion ◽  
Optic Disc ◽  
Branch Retinal Vein Occlusion ◽  
Vein Occlusion ◽  
Intravitreal Dexamethasone

Does Intravitreal Dexamethasone Implant Fragmentation Affect Clinical Outcomes in Macular Edema from Branch Retinal Vein Occlusion

2016 ◽  
Vol 236 (2) ◽  
pp. 74-80 ◽  
Author(s):  
Jong Chan Im ◽  
Jae Pil Shin ◽  
In Taek Kim ◽  
Dong Ho Park
Keyword(s):  
Macular Edema ◽  
Clinical Outcomes ◽  
Retinal Vein Occlusion ◽  
Branch Retinal Vein Occlusion ◽  
Dexamethasone Implant ◽  
Vein Occlusion ◽  
Intravitreal Dexamethasone Implant ◽  
Central Subfield Thickness ◽  
Intravitreal Dexamethasone ◽  
Rate Frequency

Purpose: The aim of this study was to evaluate the effect of intravitreal dexamethasone implant fragmentation on clinical outcomes in branch retinal vein occlusion (BRVO)-induced macular edema (ME). Methods: All consecutive patients receiving an intravitreal dexamethasone implant for BRVO-induced ME were divided into two groups depending on whether the implant was intact or had fragmented into two or more pieces on postoperative day 1. Best-corrected visual acuity (BCVA), intraocular pressure (IOP), and central subfield thickness (CST) on spectral-domain optical coherence tomography were measured for 6 months. Results: Among 68 patients, the implant was fragmented in 6 (8.8%) and intact in 62 (91.2%) eyes. The two groups did not differ in BCVA and CST at any time point (all p > 0.05). There was no difference in the ME recurrence rate, frequency of IOP elevation, and cataract progression between the two groups (all p > 0.05). Conclusion: Fragmentation seemed not to influence clinical outcomes of intravitreal dexamethasone implantation during 6 months or to alter the frequency of adverse events.

scholarly journals Accidental Intralenticular Injection of Ozurdex® for Branch Retinal Vein Occlusion: Intact Posterior Capsule and Resolution of Macular Edema

2019 ◽  
Vol 2019 ◽  
pp. 1-4 ◽  
Author(s):  
Ali Kurt ◽  
Ali Hakan Durukan ◽  
Murat Küçükevcilioğlu
Keyword(s):  
Cataract Surgery ◽  
Macular Edema ◽  
Retinal Vein Occlusion ◽  
Branch Retinal Vein Occlusion ◽  
Rare Complication ◽  
Ultrasound Biomicroscopy ◽  
Posterior Capsule ◽  
Dexamethasone Implant ◽  
Vein Occlusion ◽  
Intravitreal Dexamethasone

Purpose. We present a case of accidental intralenticular injection of Ozurdex implant in a patient with macular edema secondary to branch retinal vein occlusion. Method. A case report. Results. Intravitreal dexamethasone implant injection had been performed for macular edema due to left superior temporal vein branch occlusion to the left eye of a 78-year-old male patient. The slit-lamp examination 85 days later revealed that the dexamethasone implant was intralenticular. The best-corrected visual acuity (BCVA) was 0.16 on the Snellen chart. Cataract surgery was decided on for the cataract as there was no anterior chamber inflammation, the intraocular pressure (IOP) was normal, and the macular edema had resolved. Uneventful phacoemulsification within the bag intraocular lens placement was performed. Conclusions. Accidental intralenticular Ozurdex injection is an extremely rare complication. The surgeon must decide whether to continue to observe or intervene immediately when such a complication is encountered. Cataract surgery can be planned if the macular edema has resolved and a cataract has developed. It is important to evaluate the posterior capsule with ultrasound biomicroscopy and Scheimpflug imaging before the cataract surgery to ensure a safe surgical procedure.

Sign in / Sign up

Export Citation Format

Share Document